Hepatocellular carcinoma (HCC) is currently one of the most frequent cancers and a leading cause of cancer-related mortality worldwide. (1) Local ablation is considered the first-line treatment option for patients at early stages not suitable for surgical therapies and/ or for those patients amenable for hepatic resection but within a very early stage, or with early pathological features. (1, 2) The best outcomes have been reported in Child-Pugh A patients with small single tumors, commonly <2 cm in diameter, (3, 4) as well as in those with hypovascular features. (5, 6) Percutaneous thermal ablation of patients with larger and/or multiple tumors could be reasonable on an individual basis providing good results but without achieving response rates comparable to surgical resection. (7) However, percutaneous ablation techniques are less detrimental on liver function than surgery, offering a potentially curative therapy also for patients with advanced liver dysfunction.
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Response evaluation to radiofrequency ablation (RFA) is commonly accomplished through postprocedural radiological features, such as European Association for the Study of the Liver (EASL) criteria
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and modified Response Evaluation Criteria in Solid Tumors (mRECIST). (8) (9) (10) However, some historical data are reported in regard to histological evaluation after RFA, including a relatively small number of patients and/or of treated nodules in whom necrosis was finally assessed on the explanted liver after transplant. (11) (12) (13) (14) (15) These available data refer to the late 1990s or early 2000s, and with the refinement of ablation techniques as well as periprocedural care, it would be worthwhile to reassess the treatment success as defined by histological examination. (15, 16) Furthermore, the agreement between radiologic response to locoregional therapies (LRTs) and the degree of induced tumor necrosis remains to be fully ascertained. (17, 18) It is well known that achieving a complete pathological response (CPR) is highly predictive of excellent longterm tumor-free survival as well as a negligible risk of HCC recurrence after liver transplantation (LT). (13, 16, 19) The aims of the present study include the following:
1. Provide a histological evaluation of CPR in a large consecutive series of HCC patients treated with RFA and subsequently transplanted. 2. To measure the agreement between radiological tumor response prior to LT, according to mRECIST criteria, and the histological assessment of CPR. 3. To reassess the safety of the percutaneous ablation procedure in LT candidates.
Patients and Methods
From January 2007 to December 2016, a total of 1216 percutaneous RFAs were performed at the Interventional, Diagnostic and Therapeutic Ultrasound Unit of the S. Orsola-Malpighi Hospital, Bologna, Italy. Among them, 988 procedures were performed for HCC. A diagnosis was obtained on the basis of European guidelines released during the study period and/or tumor biopsy. In particular, a 16/64 section, using 4-phase multidetector computed tomography (CT), was used. On magnetic resonance imaging (MRI; T 1.5 ), unenhanced sequences were fat-suppressed, fast recovery, T 2 -weighted fast spin-echo and breath-hold T 1 -weighted gradient-echo/dual-echo "in and out of phase." Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (EOB Primovist; Bayer Schering Pharma, Berlin, Germany) was used for enhanced sequences. Cirrhosis had been diagnosed based on viral and/or anamnestic findings (hepatitis C virus [HCV], hepatitis B virus, and alcoholic liver disease) together with typical imaging features and clinical evidence of liver dysfunction and/or portal hypertension. The decision to submit a patient with HCC to RFA was shared among specialists during multidisciplinary meetings, including hepatologists, interventional radiologists, and surgeons. RFA was preferred in very early Barcelona Clinic Liver Cancer (BCLC) HCCs or for deeply located and larger tumors when hepatic resection was considered not applicable or not indicated in the perspective of a LT, with the aim of not complicating the eventual transplant procedure. Inclusion criteria also included a liver function staged as Child-Pugh class A or B7, no evidence of severe coagulopathy (ie, international normalized ratio >1.7), or severe thrombocytopenia (ie, platelet count ≤50 ×10 9 /L). (7) When ascites was diagnosed, it was controlled before RFA with medical therapy.
To assess CPR after RFA, patients who underwent LT between February 2007 and January 2017 were evaluated. Selection and inclusion criteria leading to the final study population are reported in Fig. 1 . No patient had undergone other therapies on the evaluated target lesions prior to RFA, and consequently, all the nodules analyzed were de novo HCCs treated first with RFA. The policy adopted in our transplant center was already published. In particular, allocation followed United Network for Organ Sharing policy since the start of the study and included, from the date of the release, priority based on the Model for End-Stage Liver Disease (MELD) score with exception points for patients with HCC and other specified conditions. (20) Tumor burden beyond Milan criteria was not considered as an absolute exclusion criteria. (21) From the end of 2016, allocation followed the Italian consensus-based approach to organ allocation in LT recommendations. (22) None of the patients received sorafenib while on the waiting list. The present study was approved by the S. Orsola-Malpighi ethical commitee.
aBlatiOn tecHniQUe
Percutaneous RFA was performed using a cool-tip single needle (Cool-Tip radiofrequency electrode; Radionics, Minneapolis, USA) having a length of 20 cm with an exposed tip of 2 or 3 cm. The length of the exposed tip used depended on the tumor dimensions. The insertion number was variable, depending on the location and the dimensions of the nodule. All the needles were inserted under ultrasonographic guidance, and the entire procedure was monitored through ultrasound to evaluate the progression of the coagulative necrosis of the nodule. In the case of a difficult location (ie, pericholecystic lesions or lesions close to extrahepatic organs), a 5% glucose solution was used to detach the target nodule from surrounding tissues. Target lesions located near hepatic veins or portal branches were not excluded from the present analysis; conversely, this feature was collected and defined as a "risky location." The generator had a maximum peak power output of 200 W and operated at 480 kHz (CC-1; Radionics). The ablation algorithm was based on tissue impedance, and ablation was considered successful when the device impedes out.
All patients received antibiotic prophylaxis before RFA with ampicillin/sulbactam or other antibiotics if clinically indicated. All procedures were performed 
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under sedation with midazolam and analgesia with fentanyl. Support oxygen therapy with nasal cannula, continuous electrocardiogram, and oxymetric monitoring were always adopted.
The Common Terminology Criteria for Adverse Events, version 5.0, was retrospectively applied to grade adverse events that occurred after the ablation procedure. (23) The length of post-RFA hospital stay was also recorded.
raDiOlOgical reSpOnSe aSSeSSMent
All patients underwent contrast-enhanced ultrasound (CEUS) with SonoVue (Bracco SpA, Milan, Italy) within 24-48 hours from ablation, either at bedside or in the ultrasound medical practice, to detect eventual bleeding and to have a first visual assessment of the obtained necrotic area (absence of hyperenhancement areas in the context of the treated lesion).
After 1 month from discharge, patients underwent dynamic studies using a 4-phase contrast CT and/or MRI. Subsequently, patients were followed with the same protocol every 3 months. In the presence of local tumor recurrence or occurrence of de novo HCCs, the treatment algorithm was the same as described before.
The last radiological assessment before LT was used for comparison between radiological and histological findings. For the CT scan, all of the studies were conducted at our institution. Tumor assessment was accomplished using a 5/2.5-mm interval, and axial images were obtained during the unenhanced phase, the arterial phase, the late arterial phase, and the portal venous or equilibrium phase. In a minority of patients (<5%), tumor response was evaluated on MRI. Thus, available radiology was retrospectively reviewed by 2 expert radiologists (C.M. and R.G.), and mRECIST criteria on the target lesion were properly applied. (8) In the very few cases of disagreement between the 2 radiologists, the final mRECIST assessment was obtained from a direct consultation between the 2 specialists. Complete response (CR) was defined as the disappearance of any enhancement of the target lesion, and partial response (PR) was defined as at least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions (Fig. 2) . (8) 
HiStOlOgical aSSeSSMent
Since 2004, a standardized method was applied to compare radiological findings to histology. This methodology represents a map of tumor location and size at the last radiological assessment before LT, which provided a guidance for pathologists when analyzing explanted livers. (24) In general, explanted livers were carefully sampled to evaluate all macroscopically suspect nodules, and neoplastic masses were thoroughly examined. The presence of partial necrosis was assessed in a semiquantitative manner as the percentage of necrotic tissue divided by total tumor tissue. The complete absence of any residual vital tumor tissue defined CPR. (13, 16, 24) 
StatiStical analYSiS
Categorical variables are reported as the number of cases and percentages, and differences between the subgroups were compared using the Fisher's exact test. The distribution of the continuous variables was checked for normality using the Kolmogorov-Smirnov test. Because a normal distribution could not be confirmed for most variables, all continuous variables were reported as medians and interquartile ranges (IQRs). Agreement between last radiological assessment before LT and histological findings was checked using the Cohen κ statistic: Agreement was considered excellent if κ was >0.80; good if κ ranged from 0.60 to 0.80; moderate if κ ranged from 0.40 to 0.60; and poor if it was <0.40. The diagnostic accuracy of radiological features in defining CPR was investigated by measuring sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs) as well as positive and negative likelihood ratios (LRs). The predictive power of early CEUS after ablation was also assessed. All the analyses were carried out using STATA software (Stata Corp, College Station, TX). A P value <0.05 was considered statistically significant.
Results
Baseline characteristics are reported in Table 1 NOTE: Data are given as n (%) and median (IQR). Examples of how nodules were counted: "In the first session, patient 23 was treated for a single HCC of 15 mm of segment 2, achieving a radiological CR; then, she developed a new HCC of 20 mm on segment 6 that was treated in the second session, again achieving initial radiological response. She finally showed a tumor relapse on the treated nodule of segment 6 and a new HCC of 18 mm on segment 4, both treated during the third session. Thus, the patient accounted for 3 distinct treated nodules." The total number of naïve HCCs treated with thermal ablation was 125. 
per-nODUle cHaracteriSticS anD OUtcOMe
The 3 sessions returned a total of 125 unique de novo HCCs treated with RFA. The per-nodule features are reported in Table 2 . During follow-up, 98 treated nodules did not show local recurrence fulfilling a sustained radiological response until LT ("1-shot" RFA, 78.4%). The median local RFS was thus not reached. The remaining 27 nodules were retreated, except 1 because of subsequent LT. CPR was observed in 77 out of 125 nodules (61.6%). Complete histological necrosis related with tumor size (P < 0.01) being observed in 76.9% of nodules within the sized <2cm (40/52), in 55.0% of nodules sized between 2 and 3 cm (33/60), and in 30.8% of nodules >3 cm (4/13). Fifty nodules were deemed to have a risky location. In these nodules, CPR was observed in 25 (50.0%), whereas the remaining 75 nodules, not in risky locations, showed CPR in 52 cases (69.3%; P = 0.04). CPR ranged between 81.2% in nodules <2 cm far from risky locations to 25.0% in nodules >3 cm in risky locations. The 98 HCCs with radiological absence of local recurrence after ablation during follow-up finally had CPR in 68.4% of the cases (67/98), which is significantly higher (P < 0.01) than the 37.0% observed in the 27 nodules showing local recurrence during follow-up and consequently retreated. No other significant relationships were found between clinical, tumoral, and ablative features and CPR. No needle tract seeding was detected.
agreeMent BetWeen raDiOlOgY anD HiStOlOgY
Radiological assessment, either with CT (75 patients) or MRI (3 patients) before LT, was available for 114 nodules. In the remaining 11, only the CEUS performed within 24-48 hours from ablation was performed and, thus, available because patients underwent transplantation before CT/MRI. The median time from last radiology to LT was 3 months (IQR, 1-4 months). Complete radiological response, according to mRECIST, was observed in 77.2% of the 114 nodules. Relationships between the last radiological assessment and CPR are reported in Table 3 . The Cohen κ was 0.48, indicating moderate agreement. The overall accuracy was 78.1%. In the 11 nodules in whom only the CEUS within 24-48 hours was available, a complete necrosis was deemed obtained in all cases, but CPR was present only in 4, returning an overall accuracy (equal to PPV) of 36.4%. 
SaFetY OF aBlatiOn prOceDUreS
The total number of RFA sessions was 92. During these sessions, 14 patients had some complications for a total of 18 (19.6%) events. The median postprocedural in-hospital stay was 2 days (IQR, 1-3 days). Details are reported in Table 4 . Notably, most of the complications were graded as minor, and morbidity in ablated patients having the largest tumor >3 cm was significantly higher (35.0%) than that of patients having the largest treated tumor ≤3 cm (9.7%; P = 0.01).
Discussion
RFA currently represents a potentially curative treatment for HCC in the early stages. (1, 2) In particular, because RFA can provide higher rates of complete necrosis of the target tumor than other LRTs, it plays a pivotal role in locoregional neoadjuvant therapies prior to LT. (7, 20) The possibility of LT returns the unique opportunity to verify the real necrosis achievable with such LRT, to fully understand its effectiveness. In the present study, we reassessed this end result to provide a reappraisal of the benefit achievable by percutaneous ablation. There are different results deserving dedicated discussion. At first, CPR was observed in 61.6% of 125 nodules at histological examination. The rate of complete necrosis was up to 76.9% in nodules <2 cm and decreased progressively with increased dimensions (65.2% when ≤3 cm), until 30.8% when >3 cm. Analyzing previous available data, Fontana et al. first reported in 2002 a complete necrosis in 59.5% of 37 nodules treated with RFA. (12) Subsequently, Pompili et al. described a complete necrosis rate of 41.3% in 46 nodules, with an increased rate for nodules <3 cm of up to 61.9%. (13) In 2004, Mazzaferro et al. reported complete necrosis in 55% of 60 nodules, which increased to 63% when nodules were <3 cm. (14) Other experiences are published, (15) (16) (17) but the largest and most recent series available to date is that of Lee et al. published in 2017 where histological examination of 113 HCC nodules treated with RFA revealed CPR in 71.7% of cases, (16) somehow higher than the present results, even if similar when analyzing CPR for tumors <3 cm (78.9% in the Lee et al. study). Quickly meta-analyzing the present results and the results from Lee et al., the CPR achievable for HCCs within transplant criteria can be estimable to approximately 66.7% (95% CI, 56.8%-76.6%, random effect model) and up to 72.7% (95% CI, 58.5%-85.5%) for tumors <3 cm. NOTE: Data are given as n (%) unless otherwise noted. Patients having the largest tumor >3 cm had a significantly higher rate of complications (7/20; 35.0%) than that of patients having the largest treated tumor ≤3 cm (7/72; 9.7%; P = 0.01). 
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A peculiar aspect of the present analysis regards the "risky location" of a treated HCC. The major obstacles of RFA are nonuniform heating in the thermal lesion and heat sinks caused by large blood vessels during treatments, which could lead to incomplete necrosis. (25) This aspect was already analyzed in the literature in regard to radiological response but, to the best of our knowledge, never in relationship with a histological assessment. (12) (13) (14) (15) (16) (17) In the present work, these difficult locations were not excluded, and it was observed that the highest CPR rate (81.2%) was achieved in nodules <2 cm regarded as not difficult cases. (26) On the opposite side, nodules >3 cm located near or close to hepatic vessels showed the lowest CPR (25.0%). Having knowledge of the achievable CPR in relationship with size and location can be useful to drive the decision making for the optimal application of LRTs.
An important quality of the present study is represented by agreement and predictive power of mRECIST criteria and the real tumor necrosis observed upon histologic analysis. In the present experience, the overall accuracy of mRECIST to predict CPR was 78.1% with a PPV of 77.3%. Similarly, Lee et al. reported an overall accuracy of approximately 70.8% with a PPV of 71.8%. Both studies included common CT scans and routine MRI, this latter was available here for a small proportion of cases (<5%). This aspect is probably responsible for this level of accuracy. In this regard, Gordic et al. recently analyzed the performance of various MRI response criteria for the prediction of CPR. (18) In a total of 97 HCCs treated with various LRTs, Gordic et al. reported a concordance statistic of approximately 81% between mRECIST and CPR. (18) The role of functional imaging such as diffusion-weighted imaging and the apparent diffusion coefficient as potential adjunct tools in response assessment after LRTs remains uncertain, with a reported concordance statistic ranging between 60% in the work of Gordic et al. and up to 85% in previous experiences. (24, 27) Taken together with all of these aspects, it can be stated that mRECIST based predominantly on CT scans leads to a PPV of approximately 74.6% (95% CI, 69.0%-80.3%, random effect model) and that the systematic application of MRI can provide a refinement of radiological correctness. (18, 24, 27) The predictive power of CEUS within 24-48 hours after RFA deserves a brief discussion. The PPV was only 36.4%. As stated in the Patients and Methods section, CEUS was performed within 24-48 hours mainly to control for the width of the necrotic area obtained and to check for complications. In such an examination, it would be very difficult to distinguish viable tumor tissue from the surrounding hyperemic area generated by the ablation itself, and viable tumor was probably interpreted as the latter. This possibly explains the end result in terms of accuracy, but the small sample on which it was calculated does not allow for robust conclusions.
In regard to safety, none of the 78 patients during the 92 sessions had an adverse event that precluded the eligibility for LT. The overall complication rate was 19.6%, but only 1 infectious complication graded as 3 (definable as major) occurred, returning a major complication rate of only 1.1%. No needle tract seeding among 125 treated nodules was detected. These data demonstrate the safety of the ablative procedure and are in keeping with the literature, and even in some instances, lower than the reported morbidity. (14, 16, 28) It should be noted that the present study only included patients submitted to RFA where microwave ablation (MWA) has now taken hold in many practice settings. However, we feel that MWA has to be considered as an emerging thermoablative treatment that joins, rather than replaces, RFA in the realm of ablative techniques. MWA and RFA use different energies to generate the complete necrosis of the target lesion. However, MWA requires larger needles, which create large areas of necrosis and are often less predictable than RFA. In patients with cirrhosis, like in the present study, it is essential to preserve the already compromised liver function. Thus, RFA can be considered more indicated than MWA. Finally, a recent high level of evidence supports that RFA and MWA are probably clinically equivalent. (29, 30) Thus, our data are consistent with a safe clinical practice of patients with cirrhosis.
The present study bears the limits of any retrospective work. Being not prospective, no inclusion criteria were applied, leading to some heterogeneity of patient population. However, because all patients were potential candidates for LT at the time of first RFA for de novo HCC, some criteria were already present and resulted in a study population that fit the tumor burden for which ablation is recommended. (1, 2) In addition, it would be of interest to include all ablated HCCs from the starting population to make more meaningful conclusions regarding mRECIST classifications. However, most of the patients were not candidates for LT, and thus, histology was impossible to obtain. We also decided not to include patients resected after ablation because the indication for partial hepatectomy would be sustained by the evidence of incomplete radiological response, therefore adding an important selection bias. Therefore, we were forced to narrow our analysis to ablated patients, with an unbiased indication to surgery, for whom histology was available through LT. Second, this is a single-center experience coming from a large tertiary hospital with a large volume of RFA patients, so the results of our study may not be generalizable to smaller hospitals. However, this aspect strengthens the general need to centralize therapeutic procedures to optimize results.
In conclusion, present data suggest that RFA can provide high CPR for HCC when radiology suggests sustained CR after the first procedure and that CPR is highest in the very early stage and/or when distant from hepatic vessels. Also, it shows that the agreement between mRECIST and histology is only moderate (Cohen κ = 0.48). Further refinements in radiological assessment, through extensive use of MRI in patients submitted solely to ablation, are needed to evaluate the effectiveness of RFA in different clinical scenarios.
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